The Alzheimer’s Screening and Prevention (ASAP) Act amends Title XVIII of the Social Security Act to make Medicare cover and pay for certain blood-based tests intended to detect pre‑symptomatic or early-stage Alzheimer’s disease and related dementias. The bill creates a new defined category of covered “Alzheimer’s disease and related dementias early detection screening tests” and requires that covered tests have an FDA regulatory authorization pathway.
The change is narrowly worded but consequential: it places these screening tests on the Medicare coverage path and requires CMS to pay for them, while leaving key implementation details — clinical eligibility, frequency, coding and pricing, and confirmatory care — to future CMS action. That combination expands access potential quickly while shifting significant policy and operational work to implementation.
Compliance officers, clinical leaders, and diagnostics companies should focus on regulatory status, evidence expectations, and billing preparations now.
At a Glance
What It Does
The bill adds a new covered item to section 1861 of the Social Security Act for Alzheimer’s early‑detection screening tests and amends payment provisions so Medicare will pay for those tests. It limits coverage to tests that have been cleared, classified, or approved by the FDA and takes effect for tests furnished on or after January 1, 2028.
Who It Affects
Affected parties include Medicare beneficiaries eligible for Part B screening services, diagnostic and laboratory firms that develop blood‑based dementia assays (including genomic sequencing vendors), clinicians who order and counsel on screening, and CMS/PBM processes that set codes and payment.
Why It Matters
This is an affirmative statutory coverage decision rather than a CMS-only coverage determination, which accelerates market access for FDA‑authorized tests but leaves open how CMS will operationalize use criteria, payment rates, and downstream care coverage — issues that determine clinical uptake and fiscal impact.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The ASAP Act inserts a new covered category into the Medicare statute and defines what counts as an Alzheimer’s early‑detection screening test. The definition requires an FDA regulatory pathway (510(k) clearance, classification under section 513(f)(2), or 515 approval) and explicitly identifies genomic sequencing blood or blood‑product tests as covered; it also authorizes the Secretary to designate “equivalent” tests including single‑analyte assays, cell‑free nucleic acid analyses, multiplex panels, whole genome/exome/transcriptome sequencing, protein expression assays, and even medical imaging that is based on biospecimens beyond blood if the Secretary deems results comparable.
Coverage applies to tests furnished on or after January 1, 2028. Separately, the bill amends the Medicare payment provision in section 1833(h)(1)(A) so that these tests are explicitly included in the list of payable items.
The statutory change does not itself set frequency limits, eligibility criteria (age, risk factors, symptomatic status), coding instructions, or reimbursement rates — those operational details will fall to CMS rulemaking, national coverage determinations, or local coverage processes.Because the statute ties coverage to FDA authorization, diagnostic manufacturers seeking Medicare reimbursement must pursue the appropriate FDA pathways now. The Secretary’s discretion to treat non‑blood biospecimens and imaging as equivalent creates a broad statutory scope that could encompass a wide range of test modalities, but CMS will need to translate that scope into practical clinical coverage rules and payment codes.
Finally, the bill is silent about required pre‑test and post‑test counseling, confirmatory testing, or how follow‑on treatments and specialist referrals are to be handled under Medicare, leaving significant downstream care and cost questions unresolved.
The Five Things You Need to Know
The bill adds a new covered category—an “Alzheimer’s disease and related dementias early detection screening test”—to section 1861 of the Social Security Act.
Coverage is limited to tests furnished on or after January 1, 2028.
The statute requires covered tests to be cleared under FDA section 510(k), classified under 513(f)(2), or approved under 515 (i.e.
cleared, classified, or approved by FDA).
The definition explicitly lists genomic sequencing of blood or blood products and gives the Secretary authority to include equivalent tests (single‑analyte, cfDNA, multiplex panels, whole genome/exome/transcriptome, protein expression, and certain imaging based on biospecimens).
The bill amends section 1833(h)(1)(A) to ensure Medicare payment authority for these screening tests but does not set reimbursement amounts, utilization limits, or clinical eligibility criteria.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title
Provides the Act’s short title: the Alzheimer’s Screening and Prevention Act of 2025 (ASAP Act). This is purely formal but signals the statute’s policy focus for implementing guidance and rulemaking references.
Adds coverage category and statutory definition (Social Security Act §1861)
Amends section 1861 to insert a new covered item for Alzheimer’s and related dementias early detection screening tests and creates a new subsection (nnn) that defines the term. The definition is twofold: first it conditions coverage on an FDA authorization pathway (510(k), 513(f)(2), or 515), and second it enumerates covered modalities—explicitly naming genomic sequencing of blood/blood products and allowing the Secretary to include functionally equivalent tests such as single‑analyte assays, cfDNA analyses, multiplex panels, whole genome/exome/transcriptome approaches, protein expression assays, and medical imaging based on biospecimens. Practically, this ties Medicare coverage to FDA status while giving CMS broad latitude to interpret what counts as an equivalent test.
Adds payment authority (Social Security Act §1833(h)(1)(A))
Modifies the Medicare payment provision to insert Alzheimer’s early detection screening tests into the statutory list of payable items. The amendment creates explicit payment authority but does not provide coding instructions, pricing methodology, frequency limits, or beneficiary eligibility rules — those implementation elements will require CMS administrative action (e.g., HCPCS codes, NCDs/LCDs, or rulemaking).
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Medicare beneficiaries at risk for Alzheimer’s disease: The statutory coverage expands potential access to blood‑based screening for older adults and other Medicare enrollees, lowering an access barrier for those who would otherwise pay privately.
- Diagnostic and laboratory companies developing blood‑based dementia assays: The bill creates a clear pathway to Medicare payment contingent on achieving FDA authorization, improving commercial viability for companies that secure the required clearances or approvals.
- Primary care clinicians and neurologists: Clinicians gain a covered diagnostic tool they can order under Medicare, which may facilitate earlier identification and referral for follow‑up care or clinical trials.
- Drug developers and clinical trial sponsors: Greater screening uptake could enlarge the pool of identified pre‑symptomatic or early‑stage patients eligible for disease‑modifying therapy trials or treatments, accelerating recruitment and market potential.
- Public health and care planners: Earlier detection could improve care planning, resource allocation, and population‑level monitoring of dementia prevalence among Medicare beneficiaries.
Who Bears the Cost
- Medicare trust funds and taxpayers: Expanded coverage and subsequent downstream services (confirmatory testing, specialist visits, long‑term care planning) could raise Medicare expenditures without an offsetting payment policy specified in the bill.
- CMS and Medicare contractors: The agency must develop coverage rules, billing codes, utilization controls, and audit/compliance processes, creating administrative workload and potential short‑term implementation costs.
- Smaller diagnostic companies without FDA authorization: Companies that cannot or choose not to pursue the specified FDA pathways may miss access to the Medicare market and face competitive pressure.
- Clinicians and health systems: Providers will face practical burdens—consenting patients, explaining screening implications, ordering confirmatory tests, and managing follow‑up care—without the statute requiring dedicated reimbursement for counseling or care coordination.
- Patients who receive false positives: Beneficiaries may experience personal costs—anxiety, additional testing, and possibly unnecessary interventions—if screening is deployed without robust clinical criteria and confirmation protocols.
Key Issues
The Core Tension
The central dilemma is between expanding access to earlier detection of Alzheimer’s disease—which could enable earlier intervention, planning, and trial enrollment—and the risk of deploying screening at scale before there is clear, population‑level evidence of clinical benefit and established pathways for confirmatory testing and downstream care, thereby increasing costs and potential harms without guaranteed improvements in outcomes.
The bill resolves one barrier (statutory Medicare coverage) but leaves open numerous consequential implementation choices. It ties coverage to FDA authorization, which helps enforce a baseline regulatory standard, but the statutory list of allowable test modalities and the Secretary’s authority to deem other tests “equivalent” is broad.
That breadth simplifies inclusion of diverse technologies but creates ambiguity about acceptable analytical and clinical validity standards across modalities and populations (e.g., performance differences by race/ethnicity or comorbidities).
Operationally, the statute is silent on who is clinically eligible (asymptomatic vs symptomatic, age or risk thresholds), how often tests may be furnished, whether positive screens must trigger confirmatory diagnostics (and whether CMS will pay for those confirmatory procedures), and whether pre‑ or post‑test counseling must be provided and reimbursed. Those gaps create a risk of rapid uptake with variable clinical utility, potential overuse, and increased downstream Medicare spending.
Another unresolved question is how the FDA pathways cited in the bill align with the evidence payers expect: a 510(k) clearance demonstrates substantial equivalence to a predicate device rather than direct demonstration of clinical utility, which may not satisfy the clinical evidence CMS considers necessary for broad screening recommendations.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.